PE20230306A1 - Anticuerpos que se dirigen a un complejo que comprende hla-i no clasico y neoantigeno y sus metodos de uso - Google Patents
Anticuerpos que se dirigen a un complejo que comprende hla-i no clasico y neoantigeno y sus metodos de usoInfo
- Publication number
- PE20230306A1 PE20230306A1 PE2022002770A PE2022002770A PE20230306A1 PE 20230306 A1 PE20230306 A1 PE 20230306A1 PE 2022002770 A PE2022002770 A PE 2022002770A PE 2022002770 A PE2022002770 A PE 2022002770A PE 20230306 A1 PE20230306 A1 PE 20230306A1
- Authority
- PE
- Peru
- Prior art keywords
- neoantigen
- complex
- hla
- methods
- antibodies targeting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063032747P | 2020-06-01 | 2020-06-01 | |
| US17/199,205 US11359023B2 (en) | 2020-06-01 | 2021-03-11 | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
| PCT/US2021/035290 WO2021247607A1 (en) | 2020-06-01 | 2021-06-01 | Antibodies targeting a complex comprising non-classical hla-i and neoantigen and their methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20230306A1 true PE20230306A1 (es) | 2023-02-13 |
Family
ID=75495114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022002770A PE20230306A1 (es) | 2020-06-01 | 2021-06-01 | Anticuerpos que se dirigen a un complejo que comprende hla-i no clasico y neoantigeno y sus metodos de uso |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US10981996B1 (https=) |
| EP (1) | EP4157882A4 (https=) |
| JP (1) | JP7650351B2 (https=) |
| KR (1) | KR20230019468A (https=) |
| CN (1) | CN116367865A (https=) |
| AR (1) | AR122501A1 (https=) |
| AU (1) | AU2021284275A1 (https=) |
| BR (1) | BR112022024275A2 (https=) |
| CA (1) | CA3174090A1 (https=) |
| CL (1) | CL2022003336A1 (https=) |
| CO (1) | CO2022018426A2 (https=) |
| CR (1) | CR20220652A (https=) |
| DO (1) | DOP2022000268A (https=) |
| EC (1) | ECSP22097197A (https=) |
| IL (1) | IL298020A (https=) |
| JO (1) | JOP20220309A1 (https=) |
| MX (1) | MX2022015114A (https=) |
| PE (1) | PE20230306A1 (https=) |
| TW (1) | TW202235439A (https=) |
| WO (1) | WO2021247607A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210253713A1 (en) * | 2018-07-23 | 2021-08-19 | Abexxa Biologics, Inc. | Antibodies targeting a complex comprising non-classical hla-i and neoantigen and their methods of use |
| CA3183756A1 (en) | 2020-05-19 | 2021-11-25 | Amgen Inc. | Mageb2 binding constructs |
| US10981996B1 (en) * | 2020-06-01 | 2021-04-20 | Abexxa Biologics, Inc. | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
| US11976120B2 (en) * | 2020-06-01 | 2024-05-07 | Boehringer Ingelheim International Gmbh | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
| KR20250009591A (ko) * | 2022-04-08 | 2025-01-17 | 티조나 테라퓨틱스 | 항-hla-g 항체 및 항-egfr 항체, 항-pd1 또는 항-pd-l1 항체, 및/또는 항-cd47을 함유하는 복합 치료법 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8039218B2 (en) * | 2002-11-14 | 2011-10-18 | John Wayne Cancer Institute | Detection of cancer cells in body fluids |
| EP1872124A4 (en) * | 2005-04-19 | 2008-06-11 | Prediction Sciences Llc | DIAGNOSIS MARKET FOR BREAST CANCER TREATMENT AND PROGRESSION AND METHOD OF USE THEREOF |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| WO2010019921A2 (en) * | 2008-08-15 | 2010-02-18 | The Regents Of The University Of California | Biomarkers for diagnosis and treatment of chronic lymphocytic leukemia |
| US20120178111A1 (en) * | 2009-09-23 | 2012-07-12 | Diamandis Eleftherios P | Methods and compositions for the detection of lung cancers |
| EP2699603B1 (en) | 2011-04-19 | 2016-03-02 | The United States of America As Represented by the Secretary Department of Health and Human Services | Human monoclonal antibodies specific for glypican-3 and use thereof |
| US10656156B2 (en) | 2012-07-05 | 2020-05-19 | Mepur Ravindranath | Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E |
| EP2961770A1 (en) | 2013-02-26 | 2016-01-06 | Roche Glycart AG | Bispecific t cell activating antigen binding molecules |
| IL263466B2 (en) | 2013-12-17 | 2023-10-01 | Genentech Inc | Anti-CD3 antibodies and methods of using them |
| CN103773775B (zh) | 2014-01-26 | 2015-11-18 | 江苏省农业科学院 | 一种人源抗虫基因及其编码的抗Cry1B毒素独特型单链抗体与应用 |
| US9950077B2 (en) | 2014-06-20 | 2018-04-24 | Bioalliance C.V. | Anti-folate receptor alpha (FRA) antibody-drug conjugates and methods of using thereof |
| US10329348B2 (en) | 2014-10-23 | 2019-06-25 | Innate Pharma | Treatment of cancers using anti-NKG2A agents |
| US10544220B2 (en) | 2015-01-08 | 2020-01-28 | Genmab A/S | Bispecific antibodies against CD3 and CD20 |
| EP3475706B1 (en) | 2016-06-27 | 2021-08-11 | Juno Therapeutics, Inc. | Mhc-e restricted epitopes, binding molecules and related methods and uses |
| EP3573997A4 (en) | 2017-01-24 | 2020-12-09 | Abexxa Biologics, Inc. | METHODS AND COMPOSITIONS INTENDED TO TARGE A COMPLEX INCLUDING A NON-CLASSIC HLA-I AND A NEO-ANTIGEN IN THE TREATMENT OF CANCER |
| CN112351795A (zh) | 2018-02-23 | 2021-02-09 | 安贝科思生物制剂公司 | 采用抗癌药剂和以包含非典型hla-i及新抗原复合物为靶点的抗体的联合抗癌疗法 |
| US20210253713A1 (en) | 2018-07-23 | 2021-08-19 | Abexxa Biologics, Inc. | Antibodies targeting a complex comprising non-classical hla-i and neoantigen and their methods of use |
| US20200291128A1 (en) | 2020-05-18 | 2020-09-17 | Abexxa Biologics, Inc. | Antibodies and methods of use thereof |
| US10981997B1 (en) * | 2020-06-01 | 2021-04-20 | Abexxa Biologics, Inc. | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
| US10981996B1 (en) * | 2020-06-01 | 2021-04-20 | Abexxa Biologics, Inc. | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
| US11976120B2 (en) * | 2020-06-01 | 2024-05-07 | Boehringer Ingelheim International Gmbh | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
-
2020
- 2020-07-10 US US16/926,306 patent/US10981996B1/en active Active
-
2021
- 2021-03-11 US US17/199,205 patent/US11359023B2/en active Active
- 2021-06-01 CN CN202180057742.6A patent/CN116367865A/zh active Pending
- 2021-06-01 JP JP2023517829A patent/JP7650351B2/ja active Active
- 2021-06-01 AR ARP210101494A patent/AR122501A1/es not_active Application Discontinuation
- 2021-06-01 EP EP21818102.2A patent/EP4157882A4/en active Pending
- 2021-06-01 US US18/000,486 patent/US20240026007A1/en active Pending
- 2021-06-01 MX MX2022015114A patent/MX2022015114A/es unknown
- 2021-06-01 WO PCT/US2021/035290 patent/WO2021247607A1/en not_active Ceased
- 2021-06-01 CA CA3174090A patent/CA3174090A1/en active Pending
- 2021-06-01 BR BR112022024275A patent/BR112022024275A2/pt not_active Application Discontinuation
- 2021-06-01 IL IL298020A patent/IL298020A/en unknown
- 2021-06-01 KR KR1020227046387A patent/KR20230019468A/ko not_active Withdrawn
- 2021-06-01 AU AU2021284275A patent/AU2021284275A1/en not_active Abandoned
- 2021-06-01 CR CR20220652A patent/CR20220652A/es unknown
- 2021-06-01 PE PE2022002770A patent/PE20230306A1/es unknown
- 2021-06-02 TW TW110120100A patent/TW202235439A/zh unknown
-
2022
- 2022-05-13 US US17/663,393 patent/US12173072B2/en active Active
- 2022-11-15 JO JOJO/P/2022/0309A patent/JOP20220309A1/ar unknown
- 2022-11-25 CL CL2022003336A patent/CL2022003336A1/es unknown
- 2022-11-28 DO DO2022000268A patent/DOP2022000268A/es unknown
- 2022-12-19 CO CONC2022/0018426A patent/CO2022018426A2/es unknown
- 2022-12-23 EC ECSENADI202297197A patent/ECSP22097197A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022024275A2 (pt) | 2023-05-02 |
| CO2022018426A2 (es) | 2022-12-30 |
| KR20230019468A (ko) | 2023-02-08 |
| US10981996B1 (en) | 2021-04-20 |
| JOP20220309A1 (ar) | 2022-11-15 |
| WO2021247607A1 (en) | 2021-12-09 |
| DOP2022000268A (es) | 2023-01-15 |
| US20240026007A1 (en) | 2024-01-25 |
| AR122501A1 (es) | 2022-09-14 |
| TW202235439A (zh) | 2022-09-16 |
| US20210371532A1 (en) | 2021-12-02 |
| US20220332831A1 (en) | 2022-10-20 |
| US12173072B2 (en) | 2024-12-24 |
| JP2023530036A (ja) | 2023-07-12 |
| IL298020A (en) | 2023-01-01 |
| CR20220652A (es) | 2023-07-03 |
| CL2022003336A1 (es) | 2023-06-23 |
| EP4157882A4 (en) | 2024-06-26 |
| JP7650351B2 (ja) | 2025-03-24 |
| EP4157882A1 (en) | 2023-04-05 |
| AU2021284275A1 (en) | 2023-01-19 |
| CA3174090A1 (en) | 2021-12-09 |
| MX2022015114A (es) | 2023-03-24 |
| US11359023B2 (en) | 2022-06-14 |
| CN116367865A (zh) | 2023-06-30 |
| ECSP22097197A (es) | 2023-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20230306A1 (es) | Anticuerpos que se dirigen a un complejo que comprende hla-i no clasico y neoantigeno y sus metodos de uso | |
| PE20230374A1 (es) | Anticuerpos dirigidos a un complejo que comprende hla-i no clasico y neoantigeno y sus metodos de uso | |
| UY37694A (es) | Dominios de unión a antígeno humanizados y métodos de uso | |
| AR117727A1 (es) | Anticuerpos que se unen a cd3 | |
| PE20220278A1 (es) | Dominios variables de anticuerpos que se dirigen al receptor nkg2d | |
| PE20191661A1 (es) | Inhibidores de tgf beta1 isoforma-especificos contexto-permisivos y uso de los mismos | |
| AR109882A1 (es) | Anticuerpos monoclonales neutralizantes anti-tl1a | |
| CU24663B1 (es) | Dominio de unión a antígeno anti-trbc1, receptor de antígeno quimérico, anticuerpo y acoplador biespecífico de células t que comprenden el mismo | |
| AR104280A1 (es) | Terapia de combinación con factores de coagulación y anticuerpos multiespecíficos | |
| SA523440043B1 (ar) | أجسام مضادة ضد cd3 إبسيلون جديدة | |
| PE20190737A1 (es) | Anticuerpos anti-cd27 | |
| PE20211887A1 (es) | Receptor antigenico quimerico (car) que comprende un dominio de union a antigenos, el cual se une selectivamente a la region constante del tcr beta 1 (trbc1) o trbc2 de celulas t | |
| PE20120475A1 (es) | Anticuerpos especificos para dkk-1 | |
| PE20220763A1 (es) | Materiales y metodos para modular la inmunidad mediada por celulas t | |
| NZ594682A (en) | Fully human antibodies specific to cadm1 | |
| PE20230839A1 (es) | Agentes de union a lair-1 y metodos para su uso | |
| PE20231080A1 (es) | Anticuerpos que se unen a cd3 y cd19 | |
| PE20230616A1 (es) | Anticuerpos que se unen a cd3 y folr1 | |
| MX2022005949A (es) | Anticuerpos anti-ror-2 y metodos de uso. | |
| AR096601A1 (es) | Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso | |
| PE20232050A1 (es) | Anticuerpos anti-cd19 y estructuras car-t | |
| AR126154A1 (es) | Agentes aglutinantes biespecíficos que se unen a cldn18.2 y cd3 | |
| CO2022010294A2 (es) | Anticuerpos cd163 o proteinas de union | |
| PE20191319A1 (es) | Anticuerpos novedosos contra el factor xi y sus usos | |
| WO2022174103A3 (en) | Monoclonal antibodies specific for human ror1 |